LEQEMBI (lecanemab-irmb) injection
LEQEMBI is a prescription medicine used to treat osteoporosis. It is not commercially registered or marketed in India, but eligible patients can legally access it through the Named Patient Program (NPP). This pathway allows individuals to import the medication for personal use by obtaining specific regulatory clearance from the CDSCO.
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
LEQEMBI (lecanemab-irmb) injection
Lecanemab is indicated for the treatment of Alzheimer's disease in people who have mild cognitive impairment or mild dementia, but not in people who already have moderate or severe dementia.
LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer’s disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia. In clinical trials, it demonstrated modest efficacy in reducing relative cognitive decline compared to placebo. The most common side effects of lecanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid.
It was granted accelerated approval for medical use in the United States in January 2023, and fully approved by the FDA in July 2023. Lecanemab was approved for medical use in South Korea in May 2024, and in Mexico in December 2024.
LEQEMBI (lecanemab-irmb) injection, for intravenous use Initial U.S. Approval: 2023
—————-
Current Indication: Treat Alzheimer’s disease
—————-
Marketed By: Eisai Inc
—————-
Approval Date: : 2023
—————-
Active ingredients: lecanemab-irmb
—————-
Inactive ingredients: : arginine hydrochloride, histidine, histidine hydrochloride monohydrate, polysorbate 80, and water
for injection.
Injection:
• 500 mg/5 mL (100 mg/mL) solution in a single-dose vial
• 200 mg/2 mL (100 mg/mL) solution in a single-dose vial
Find Reference Updates
- For LEQEMBI (lecanemab-irmb) injection And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions.
- FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
- FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
